Morgan Stanley Maintains Overweight on CVS Health, Lowers Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Erin Wright has maintained an 'Overweight' rating on CVS Health (NYSE:CVS) but lowered the price target from $120 to $110.
August 04, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an 'Overweight' rating on CVS Health but lowered the price target from $120 to $110.
The news is directly related to CVS Health. While the 'Overweight' rating suggests that Morgan Stanley expects the stock to outperform, the lowering of the price target may create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100